MedTrace Logo

Vaccine Therapy in Treating Patients With Malignant Melanoma

NCT00128583 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with malignant melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

polyvalent melanoma vaccine

Sponsors & Collaborators

  • CancerVax Corporation

    lead INDUSTRY

Principal Investigators

  • Linda Strause · CancerVax Corporation

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00128583 on ClinicalTrials.gov